Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03228810 · ClinicalTrials.gov registry record
Genetic Biomarker Discovery for Metastatic Prostate Cancer
A clinical trial, sponsored by Mayo Clinic.
- Completed
- Registry status
- 4
- Enrollment target
NCT03228810: Completed study, sponsored by Mayo Clinic.
NCT03228810 is a clinical trial that has completed, run by Mayo Clinic. The registered enrollment target is 4 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03228810 has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- 4 participants
- Enrollment target
Study Summary
Biomarkers from circulating cell-free tumor DNA in peripheral blood will identify patients with metastatic prostate cancer diagnosed with C11 choline PET/CT who will benefit from metastasis-directed radiation, ablative therapies, and/or surgery. Tissue and blood will be collected before treatment. If patients receive androgen deprivation, then blood will be collected after neoadjuvant androgen deprivation but before radiation, ablative therapies, or surgery. Subsequent samples will be obtained at 3 months and 6 months following treatment, after which no further patient contact will occur.
Interventions
- OTHER Blood draw
- PROCEDURE Tissue biopsy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2017-05-02 |
| Est. Completion | 2019-04-09 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03228810
The ClinicalTrials.gov registry entry for NCT03228810 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Blood draw is the first listed.
NCT03228810 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03228810 about?
NCT03228810 is a clinical study titled "Genetic Biomarker Discovery for Metastatic Prostate Cancer". Biomarkers from circulating cell-free tumor DNA in peripheral blood will identify patients with metastatic prostate cancer diagnosed with C11 choline PET/CT who will benefit from metastasis-directed radiation, ablative therapies, and/or surgery. Tissue and blood will be collected before treatment. I...
What is the current status of trial NCT03228810?
This trial is currently completed. The enrollment target is 4 participants. The study started on 2017-05-02. Estimated completion is 2019-04-09.
What interventions are being tested in trial NCT03228810?
The interventions under investigation include: Blood draw (OTHER), Tissue biopsy (PROCEDURE).
Who is sponsoring clinical trial NCT03228810?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.